Last updated on November 2019

Transthyretin-Associated Amyloidosis Outcome Survey (THAOS)


Brief description of study

THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin-associated amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate.

The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.

Detailed Study Description

n/a NA

Clinical Study Identifier: NCT00628745

Find a site near you

Start Over

University of Chicago Medical Center IRB

Chicago, IL United States
8.86miles
  Connect »

University of Chicago Medical Center

Chicago, IL United States
8.86miles
  Connect »